Aurinia's Lupkynis Shows Sustained Renal Response Rates In Lupus Nephritis PatientsBenzinga • 05/21/21
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus NephritisBusiness Wire • 05/20/21
Is the Options Market Predicting a Spike in Aurinia (AUPH) Stock?Zacks Investment Research • 05/13/21
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus NephritisBusiness Wire • 05/10/21
Aurinia Pharma's Stock Gains After Lupkynis Data From Late-Stage Lupus Nephritis Study Published In LancetBenzinga • 05/10/21
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The LancetBusiness Wire • 05/10/21
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/07/21
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/21
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational HighlightsBusiness Wire • 05/06/21
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021Business Wire • 04/28/21
Aurinia Pharmaceutical Stock Showing A Potential Reversal Pattern: 4 Key Levels To WatchBenzinga • 04/20/21
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor ConferenceBusiness Wire • 04/15/21
Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data ShowsBenzinga • 04/08/21
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical MeetingsBusiness Wire • 04/08/21
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence ReportBusiness Wire • 03/15/21
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor ConferencesBusiness Wire • 03/02/21
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational HighlightsBusiness Wire • 02/24/21